Evaluating natalizumab first-line and later-line use in multiple sclerosis: a US claims database analysis.

ABSTRACT:

Background

Limited information exists on the healthcare resource utilization (HCRU) associated with real-world natalizumab used as a first-line (1L) versus later-line (2L+) treatment in multiple sclerosis (MS).

Objectives

To describe natalizumab use in newly diagnosed MS patients treated as 1L or 2L+ and evaluate unadjusted annualized relapse rates (ARR) and MS-related HCRU before and after treatment initiation.

Design

This retrospective observational study utilized Komodo Health Sentinel claims data from October 2015 to August 2022. The study included adults diagnosed with incident MS who initiated natalizumab treatment, with insurance coverage for at least 12 months before diagnosis and 24 months after. The index date was the first natalizumab claim on or after the

SUBMITTER: Avila RL 

PROVIDER: S-EPMC11912164 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature